Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Drug Manufacturers Association Secretary General Touts Prospects (Asia)

This article was originally published in PharmAsia News

Executive Summary

Indian Drug Manufacturers Association (IDMA) secretary general Daara Patel says Asia's pharmaceutical industry is expanding, with especial strength in China and India, and with strong investment backing from global companies. India itself is well positioned to take advantage of the downward pressure on pharmaceutical prices because India's domestic industry can supply high-quality affordable drugs and active pharmaceutical ingredients to global markets. Patel predicts that Asia's overall pharmaceutical market will surpass the markets in the United States and Europe in the next few years. Japan and India also will soon be developing a steady pipeline of innovative drugs, he predicts. Today Korea, Singapore, and India-based scientists are pioneering new research in stem cells and therapeutic cloning. Asian companies looking to develop new drugs will have to look for larger partners, just like U.S. biotechnology start-ups usually partner with capital-rich corporations for clinical testing and market help. Patel says Asian pharmaceutical companies have a global advantage because they can "retain their cost advantage while matching the quality standards of the West." However, he warns that cost advantage is not enough, and that "a favorable regulatory environment that assures compliance with global norms are the other two legs underpinning success." (Click here for more

You may also be interested in...



House Committees Want BARDA Coronavirus Vaccine, Treatment Contract Info

Request for documents and a briefing is part of efforts to ensure federal programs are ‘protected from price gouging.’

Merck’s Frazier Urges Businesses To Use ‘Every Instrument At Their Disposal’ To Reduce Racial Inequity

‘What we have to guard against is that when the streets quiet down … a lot of people are going to go back to their normal lives,’ Merck CEO Ken Frazier says in an interview with CNBC.

Merck’s Frazier Urges Businesses To Use ‘Every Instrument At Their Disposal’ To Reduce Racial Inequity

‘What we have to guard against is that when the streets quiet down … a lot of people are going to go back to their normal lives,’ Merck CEO Ken Frazier says in an interview with CNBC.

UsernamePublicRestriction

Register

RS009715

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel